Jiangsu Kanion Pharmaceutical Co.,Ltd.
600557.SS · SHH
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 4.35B | 3.14B | 454.81M | 434.47M | 0.75 |
| 2023 FY | 4.86B | 3.61B | 460.80M | 464.16M | 0.81 |
| 2024 FY | 3.90B | 2.83B | 384.52M | 391.86M | 0.68 |
| 2025 FY | 3.27B | 2.28B | 249.16M | 303.93M | 0.54 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 6.80B | 1.86B | 1.60B | 11.86M | 4.75B |
| 2023 FY | 7.12B | 1.74B | 1.97B | 1.93M | 5.19B |
| 2024 FY | 6.91B | 2.20B | 2.20B | 547.97M | 4.51B |
| 2025 FY | 6.86B | 1.72B | 2.15B | 407.36M | 4.82B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 995.94M | -211.09M | 784.85M | -2.49M | 663.86M |
| 2023 FY | 972.32M | -297.48M | 743.52M | -128.51M | 370.95M |
| 2024 FY | 702.49M | -476.69M | 225.80M | -213.58M | 185.82M |
| 2025 FY | 620.85M | -521.78M | 99.08M | — | -46.97M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 10.86B | 9.27B | — | — | — |
| 2023 FY | 12.20B | 10.23B | — | — | — |
| 2024 FY | 7.85B | 6.20B | — | — | — |
| 2025 FY | 7.99B | 6.25B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 764.02M | 512.58M | 80.28M | 58.96M | 0.10 |
| 2025 Q3 | 701.11M | 463.80M | 75.36M | 57.27M | 0.10 |
| 2025 Q4 | 950.21M | 725.23M | 110.48M | 104.29M | 0.18 |
| 2026 Q1 | 831.27M | 623.22M | 96.64M | 79.28M | 0.14 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 6.83B | 1.98B | 2.06B | 791.53K | 4.66B |
| 2025 Q3 | 6.74B | 1.83B | 2.16B | 44.02M | 4.71B |
| 2025 Q4 | 6.86B | 1.72B | 2.15B | 407.36M | 4.82B |
| 2026 Q1 | 6.89B | 1.79B | 2.04B | 1.06M | 4.90B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 67.41M | -110.17M | -42.75M | — | -32.48M |
| 2025 Q3 | 201.83M | -128.94M | 72.90M | — | 95.69M |
| 2025 Q4 | 269.81M | -186.11M | 83.69M | — | -9.27M |
| 2026 Q1 | 68.54M | -187.66M | -119.12M | — | -112.14M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 8.61B | 6.55B | — | — | — |
| 2025 Q3 | 8.58B | 6.46B | — | — | — |
| 2025 Q4 | 7.99B | 6.25B | — | — | — |
| 2026 Q1 | 7.72B | 5.68B | — | — | — |